Before the Break: Identifying and Treating Patients At Risk for Osteoporosis
Release Date: July-22-11
Credit Expiration Date: July-22-12
Physicians in family medicine, general medicine, and internal medicine, as well as other healthcare professionals involved or interested in the care of patients with osteoporosis.
0.5 Credit Hour
0.5 Prescribed Credit
Osteoporosis is a major public health problem. In the United States an estimated 10 million people have osteoporosis. Complications of osteoporosis include fractures, disability, and chronic pain. Fractures lead to significant loss in quality of life with reduced mobility and often lead to premature death. Primary care providers are uniquely positioned to play a substantial role in detecting and managing osteoporosis. Unfortunately, measures to identify and treat women and men at risk are underused in clinical practice.
The goal of this continuing medical education activity is to increase primary care providers' knowledge of the rationale and importance of osteoporosis screening and treatment, as well as to expand their ability to implement effective strategies to prevent, detect, and treat osteoporosis, ultimately helping patients avoid much of the damaging consequences this disease.
Stuart L. Silverman, MD, FACP, FACR
Medical Director Bone Center of Excellence, Cedars-Sinai Medical Center
Clinical Professor of Medicine and Rheumatology, UCLA School of Medicine
Beverly Hills, CA
Adity Bhattacharyya MD, FAAFP
UMDNJ-RWJMS Family Medicine Residency Program at Capital Health
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy and NJAFP are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
Dr. Silverman discloses the following relationships:
Speaker’s Bureau: Amgen, Lilly, Novartis, Pfizer/Wyeth, Roche Pharmaceuticals; Consultant: Amgen, Genentech, Lilly, Novartis, Pfizer/Wyeth, Roche Diagnostics, Roche Pharmaceuticals, Warner Chilcott; Research Support: Lilly, Pfizer/Wyeth, Warner Chilcott
Dr. Bhattacharyya has no relevant financial conflicts to disclose.
Additional planning committee members, Medical Communications Media, Purdue University College of Pharmacy, and NJAFP staff have the following to disclose.
Ms. Sinclair has no relevant financial conflicts to disclose.
Dr. Koh-Knox has no relevant financial conflicts to disclose.
Ms. Barrett has no relevant financial conflicts to disclose.
Ms. Thier has no relevant financial conflicts to disclose.
Dr. Paczolt discloses that as former Medical Director at a promotional medical communications company, her work received funding from Gilead Sciences, Novartis, Merck, and Ortho-Mcneil Janssen.
ACCME ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and Medical Communications Media. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material activity, Before the Break: Identifying and Treating Patients At-Risk for Osteoporosis, has been reviewed and is acceptable for up to 0.50 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins July 22, 2011. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an education grant from Amgen Inc.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Purdue University College of Pharmacy, NJAFP, or Amgen Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.